FOXO:NYE-FOXO Technologies Inc. (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 0.176

Change

+0.00 (+1.73)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+0.48 (+0.71%)

USD 10.78B
DOCS Doximity Inc

+0.46 (+1.06%)

USD 7.70B
WEAV Weave Communications Inc

+0.47 (+3.75%)

USD 0.89B
AMWL American Well Corp

+0.29 (+3.20%)

USD 0.14B
MPLN MultiPlan Corporation

+1.02 (+12.78%)

USD 0.12B
OWLT Owlet Inc

-0.07 (-1.53%)

USD 0.07B
STRM Streamline Health Solutions In..

+2.37 (+1,185.64%)

USD 0.01B
LFMDP LifeMD Inc Preferred Series A

-0.25 (-1.12%)

N/A
PHR Phreesia Inc

+0.12 (+0.54%)

N/A
VEEV Veeva Systems Inc Class A

+0.14 (+0.07%)

N/A

ETFs Containing FOXO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.95% 42% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.95% 42% F 3% F
Trailing 12 Months  
Capital Gain -85.57% 17% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.57% 17% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -44.77% N/A N/A N/A F
Dividend Return -44.77% N/A N/A N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.68% N/A N/A 20% F
Risk Adjusted Return -98.01% N/A N/A 1% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector